The trajectory of companies tied to Sildenafil's legacy presents a challenging investment picture . While the initial success generated substantial profits , generic alternatives have significantly impacted sales . Investing in related pharmaceutical companies now requires a thorough assessment of intellectual property safeguards, evolving medical